{"id":2245,"date":"2021-09-24T17:39:34","date_gmt":"2021-09-24T21:39:34","guid":{"rendered":"https:\/\/lifescivoice.com\/?p=2245"},"modified":"2021-09-24T17:42:04","modified_gmt":"2021-09-24T21:42:04","slug":"takeda-pharmaceutical-gets-fda-nod-for-lung-cancer-drug-exkivity","status":"publish","type":"post","link":"https:\/\/lifescivoice.com\/takeda-pharmaceutical-gets-fda-nod-for-lung-cancer-drug-exkivity\/","title":{"rendered":"Takeda Pharmaceutical gets FDA nod for lung cancer drug Exkivity"},"content":{"rendered":"\n<p>The U.S. Food and Drug Administration had approved Takeda Pharmaceutical Co.\u2019s drug, Exkivity, to treat a particular type of lung cancer, the Japanese pharmaceutical company announced on 15<sup>th<\/sup> September.<\/p>\n\n\n\n<p>The drug has been approved only for patients having a particular gene mutation in non-small cell lung cancer (NSCLC) known as EGFR Exon 20 insertion, whose disease has grown during or after the chemotherapy. &nbsp;&nbsp;<\/p>\n\n\n\n<p>Exkivity\u2019s approval from the FDA was explicitly based on some affirmative and meaningful results yielded from early-to-mid stage trials carried out on 114 patients having NSCLC, over a period of 18 months on average, the company said, which is subjected to the verification and description of clinical benefit through confirmatory trials.<\/p>\n\n\n\n<p>However, the drug is marketed with a boxed warning indicating potential risks relating to the heart toxicity, heart rhythm disturbance and lung diseases.<\/p>\n\n\n\n<p>According to the World Health Organization, NSCLC is the most common type of lung cancer constituting up to 85% of the estimated 2.2 million cases of lung cancer diagnosed every year globally.&nbsp;&nbsp;&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The U.S. Food and Drug Administration had approved Takeda Pharmaceutical Co.\u2019s drug, Exkivity, to treat a particular type of lung cancer, the Japanese pharmaceutical company announced on 15th September. The drug has been approved only for patients having a particular gene mutation in non-small cell lung cancer (NSCLC) known as EGFR Exon 20 insertion, whose [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2247,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[35],"tags":[545,61,544,107],"class_list":{"0":"post-2245","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-clinical","8":"tag-exkivity","9":"tag-fda","10":"tag-lung-cancer","11":"tag-takeda"},"_links":{"self":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/2245","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/comments?post=2245"}],"version-history":[{"count":0,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/2245\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/media\/2247"}],"wp:attachment":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/media?parent=2245"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/categories?post=2245"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/tags?post=2245"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}